IRIDEX opened higher at $0.70, compared with its previous close of $0.65. In the last trading session, the stock traded between $0.70 and $0.73. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in IRIDEX is now worth
$ 7.89
Resulting in a loss of
$ 92.11 (92.11%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.06 (+8.71%)
Day High
$0.73
Day Low
$0.70
Day Open
$0.70
Prev Close
$0.65
Volume
4,417
1W Return
0.85%
1M Return
-23.16%
3M Return
-19.77%
6M Return
-32.38%
1Y Return
-40.34%
Fundamentals
Market Cap ($ Mn)
12
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-3,630.93%
ROCE
-26.82%
EPS (TTM)
$-0.07
Investment Returns
1 Week
0.85%
1 Month
-23.16%
3 Months
-19.77%
6 Months
-32.38%
9 Months
-50.35%
Financials
Quarterly
All values in $ Mn
11.9
Mar 25
13.6
Jun 25
12.5
Sep 25
14.7
Dec 25
11.8
Mar 26
12.6
Jun 26
Updates
12Oct
Iridex study shows MicroPulse cuts glaucoma IOP by 37% over two years
Mean intraocular pressure dropped from 22.32 mmHg to 14.05 mmHg over 24 months. Treatment success rates reached 86% in POAG eyes and 81% in PACG eyes. Mean use of topical IOP-lowering medications fell from 2.96 to 2.38 per patient. All patients discontinued oral acetazolamide post-treatment without reinitiation. No complications or visual acuity reductions were reported during the study.
1mo ago
19Aug
Iridex Q2 revenue misses estimate as loss widens to $0.07
Iridex Corporation reported Q2 2026 revenue of $12.6 million, missing estimates, with a net loss widening to $1.3 million. Glaucoma probe volumes rose 35%, offsetting declines in the Retina segment due to regional headwinds. The company delivered positive operating cash flow and reaffirmed full-year revenue guidance of $51-53 million, citing strategic cost-cutting measures and a headquarters relocation.
2mo ago
19Aug
Iridex Latest Results: FY26 sales guidance affirmed at $51M-$53M, below est
Iridex reaffirmed its FY2026 sales guidance in the range of $51.000 million to $53.000 million. The affirmed guidance range falls below the analyst estimate of $53.227 million. No revision to the previously stated outlook was indicated.
2mo ago
20Jul
Iridex expands EyeProGPO product offering with EndoProbe Handpieces
Iridex Corporation has expanded its EyeProGPO product offering to include EndoProbe Handpieces, providing preferred pricing to over 4,300 members. The addition strengthens collaboration with EyeProGPO, offering broader access to retina laser systems and delivery devices for vitreoretinal procedures.
3mo ago
10Jun
Iridex Corporation to present at Planet MicroCap Las Vegas 2026
Iridex Corporation will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, at 4:00 pm PT. The presentation will be accessible via live and archived webcast on the company's website. Iridex specializes in laser-based medical systems for treating glaucoma and retinal diseases.
